Medicaid covers testosterone replacement therapy in 47 states as of 2026, though coverage requirements vary significantly by state. Most states require prior authorization, two testosterone blood tests below 300 ng/dL taken between 7-11 AM, and documented symptoms of hypogonadism. Coverage typically includes testosterone injections, gels, and patches but excludes newer formulations like nasal gels or implants in many states. Prior authorization approval rates range from 65% in restrictive states like Texas to most in more liberal coverage states like California and New York. The average processing time for prior authorization is 5-7 business days, though some states allow for expedited 48-hour approvals for patients with documented pituitary disorders. Three states (Alabama, Wyoming, and Alaska) have limited coverage that only applies to specific conditions like Klinefelter syndrome or pituitary tumors.
Key Takeaways
- 47 states provide Medicaid coverage for testosterone replacement therapy with prior authorization requirements
- Two morning testosterone tests below 300 ng/dL are required in most states for approval
- Coverage includes injections, gels, and patches but often excludes newer formulations
- Prior authorization approval rates vary from 65% to most depending on state requirements
- Processing time averages 5-7 business days for standard requests
State-by-State Coverage Requirements
Coverage requirements differ substantially across states, with liberal coverage states like California, New York, and Massachusetts requiring only two testosterone blood tests below 300 ng/dL and documented symptoms. These states approve 85-89% of prior authorization requests and cover generic testosterone cypionate, enanthate, gels, and patches. Moderate coverage states including Florida, Illinois, and Ohio add requirements for failed lifestyle interventions and may require endocrinologist consultations for patients under 40. Restrictive states like Texas, Georgia, and North Carolina require additional criteria such as bone density scans, documented infertility, or specific symptom severity scores. The approval process in restrictive states can take up to 14 days and approval rates drop to 65-70%. Similar to how patients explore peptide therapy options for hormone optimization, testosterone replacement therapy coverage varies widely based on state Medicaid policies.Required Documentation and Testing
Most states mandate specific documentation protocols that mirror clinical guidelines from the American Urological Association. Two separate testosterone blood tests drawn between 7-11 AM at least one week apart showing levels below 300 ng/dL represent the universal baseline requirement. Additional testing often includes luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prolactin levels to rule out secondary causes. States typically require documentation of at least three hypogonadal symptoms from a standardized list including decreased libido, erectile dysfunction, fatigue, decreased muscle mass, or mood changes. Some states require validated questionnaire scores like the Androgen Deficiency in Aging Males (ADAM) questionnaire. The documentation must come from qualified providers, with 35 states accepting primary care physician orders while 12 states require specialist involvement for initial prescriptions.Covered Formulations and Limitations
Generic testosterone formulations receive universal coverage across Medicaid programs, with testosterone cypionate injections representing the most commonly covered option due to cost-effectiveness. Testosterone enanthate injections, generic gels (1% and 1.62%), and patches qualify for coverage in most states. Brand name products like AndroGel, Testim, or Axiron typically require step therapy, meaning patients must try generic alternatives first. Newer formulations including nasal gels (Natesto), subcutaneous pellets, and buccal tablets face coverage restrictions in 38 states. Monthly injection costs through Medicaid average $15-25 for generics compared to $300-400 for uninsured patients. Some patients also explore complementary approaches like Sermorelin therapy for natural growth hormone support, though these peptide treatments typically require separate coverage considerations.Prior Authorization Process and Timeline
The prior authorization process requires healthcare providers to submit detailed clinical documentation through state-specific portals or fax systems. Standard processing times range from 5-7 business days, with expedited reviews available in 28 states for urgent cases involving documented pituitary disorders or testosterone levels below 150 ng/dL. Approval rates correlate directly with documentation quality, with complete submissions including lab results, symptom documentation, and provider notes achieving 15-20% higher approval rates. Denied requests can be appealed within 60 days in most states, with medical review board hearings available for complex cases. The appeals process adds an additional 14-21 days but succeeds in approximately 35% of cases when additional clinical evidence is provided. Providers familiar with hormone optimization often coordinate care that may include discussions about other therapeutic options like Ipamorelin therapy for growth hormone support.Frequently Asked Questions
What testosterone level qualifies for Medicaid coverage?
Most states require two separate morning testosterone tests showing levels below 300 ng/dL for Medicaid coverage eligibility. Tests must be drawn between 7-11 AM at least one week apart to account for natural testosterone fluctuations. Some states accept levels up to 350 ng/dL if accompanied by severe symptoms and additional hormone testing abnormalities. The tests must be performed by certified laboratories and documented by qualified healthcare providers.
Check if TRT is right for you
Take a free 2-minute assessment to see if testosterone replacement therapy could help restore your energy, mood, and vitality.
Start Free Assessment →View data table
| Category | Patients Reporting Improvement (%) | Detail |
|---|---|---|
| Energy | 78 | Improves in 2-4 weeks |
| Mood | 72 | Stabilizes in 4-6 weeks |
| Libido | 82 | Returns in 3-6 weeks |
| Muscle | 65 | Visible at 3-4 months |
| Body Fat | 58 | Reduces over 6+ months |
How long does Medicaid prior authorization take for testosterone?
Standard prior authorization processing takes 5-7 business days in most states, though expedited 48-hour reviews are available for urgent cases in 28 states. Expedited processing typically applies to patients with testosterone levels below 150 ng/dL or documented pituitary disorders. Complete documentation with lab results, symptom questionnaires, and detailed provider notes can reduce processing time by 1-2 days in many states.
Does Medicaid cover brand name testosterone products?
Medicaid typically covers generic testosterone formulations first, requiring step therapy for brand name products. Generic testosterone cypionate injections and 1% gels receive universal coverage, while brand names like AndroGel or Testim require prior failure of generic alternatives. Some states allow brand name coverage with additional copays of $10-15 per prescription. Newer formulations like nasal gels face significant coverage restrictions across most Medicaid programs.
Can I get testosterone therapy through Medicaid if I'm under 40?
Medicaid covers testosterone replacement therapy for men under 40 with documented hypogonadism, though requirements may be more stringent. Many states require endocrinologist consultation for patients under 40 to rule out reversible causes of low testosterone. Additional testing including pituitary imaging or genetic screening may be required. Approval rates for men under 40 average 70-75% compared to most for men over 40, primarily due to increased scrutiny for secondary causes.
What happens if my Medicaid testosterone prior authorization is denied?
Denied prior authorization requests can be appealed within 60 days through state-specific appeals processes. Appeals require additional clinical documentation, often including specialist consultations or more complete hormone testing. Success rates for appeals average 35% when new evidence is provided. Some states offer expedited appeal reviews for urgent cases. Alternative coverage options may include patient assistance programs from manufacturers or switching to generic formulations with lower coverage barriers.
Related guides
- Does Insurance Cover TRT
- Does Kaiser Cover TRT? Insurance Guide
- Does Aetna Cover TRT? 2026 Coverage Guide
- Does Blue Cross Blue Shield Cover TRT?
- Does United Healthcare Cover TRT?
Sources
- American Urological Association. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. PMID: 29601923
- Centers for Medicare & Medicaid Services. State Medicaid Coverage of Hormone Replacement Therapy. 2026 Annual Report. CMS Publication No. 2026-HRT-001
- Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline Amendment 2023. J Urol. 2023;209(6):1091-1099. PMID: 37073935
- National Association of Medicaid Directors. Prior Authorization Requirements for Testosterone Therapy: State Comparison Study. Health Affairs. 2026;45(3):456-463
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364
- Kaiser Family Foundation. Medicaid Coverage of Prescription Drugs: State Policies and Spending. 2026 State Health Facts Database. Retrieved April 2026
- Morgentaler A, Traish AM, Kacker R, et al. Causes of testosterone deficiency and current testosterone therapy practices among urologists. Rev Urol. 2017;19(1):1-10. PMID: 28522926
- Academy of Managed Care Pharmacy. Testosterone Replacement Therapy: Clinical and Economic Considerations. J Manag Care Spec Pharm. 2025;31(8):892-901
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →